BELLUS Health (BLU) Shares Up 11.5% Following Insider Buying Activity

BELLUS Health Inc (TSE:BLU) shot up 11.5% during mid-day trading on Wednesday after an insider bought additional shares in the company. The stock traded as high as C$1.29 and last traded at C$1.26. 283,158 shares traded hands during trading, an increase of 115% from the average session volume of 131,515 shares. The stock had previously closed at C$1.13.

Specifically, Director Francesco Bellini bought 31,600 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were acquired at an average price of C$1.14 per share, with a total value of C$36,024.00. Following the completion of the transaction, the director now owns 725,489 shares in the company, valued at C$827,057.46.

The stock has a market cap of $190.02 million and a PE ratio of -16.27.

BELLUS Health (TSE:BLU) last released its earnings results on Thursday, February 21st. The company reported C($0.02) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of C($0.02). The company had revenue of C$0.01 million during the quarter, compared to analyst estimates of C$0.01 million. On average, equities analysts forecast that BELLUS Health Inc will post -0.069999999469697 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “BELLUS Health (BLU) Shares Up 11.5% Following Insider Buying Activity” was first published by Mayfield Recorder and is owned by of Mayfield Recorder. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://mayfieldrecorder.com/2019/05/03/bellus-health-blu-shares-up-11-5-following-insider-buying-activity-2.html.

BELLUS Health Company Profile (TSE:BLU)

BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.

Further Reading: Do stock splits help investors?

Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.